ACER Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Acer Therapeutics Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Acer Therapeutics Inc. (NASDAQ: ACER) to Zevra Therapeutics, Inc. for 0.121 of a share of Zevra’s common stock for each share of Acer’s common stock is fair to Acer shareholders. Additionally, Acer stockholders would receive non-transferable Contingent Value Rights entitling them to receive up to $34 million in cash upon the achievement of certain commercial milestones for OLPRUVA, and up to an additional $42 million in cash upon the achievement of certain regulatory milestones for OLPRUVA and EDSIVO.

Halper Sadeh encourages Acer shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at [phone] or [e-mail] or [e-mail].

The investigation concerns whether Acer and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Acer shareholders; (2) determine whether Zevra is underpaying for Acer; and (3) disclose all material information necessary for Acer shareholders to adequately assess and value the merger consideration. On behalf of Acer shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.

Halper Sadeh encourages Acer shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at [phone] or [e-mail] or [e-mail].

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.